# Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome

> **NCT04400032** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 15 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Covid19

## Interventions

- **BIOLOGICAL:** Mesenchymal Stromal Cells

## Key facts

- **NCT ID:** NCT04400032
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2021-04-22
- **Final completion:** 2021-04-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-04-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400032, "Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04400032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*